Goldman Sachs Group Inc Alnylam Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 356,100 shares of ALNY stock, worth $90.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

356,100

Previous 514,667 30.81%

Holding current value

$90.1 Million

Previous $125 Million 21.68%

% of portfolio

0.02%

Previous 0.02%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$233.81 - $287.01 $37.1 Million - $45.5 Million	-158,567 Reduced 30.81%	356,100 $98 Million
Q2 2024 Aug 13, 2024	BUY	$143.31 - $247.0 $36.5 Million - $62.9 Million	254,648 Added 97.93%	514,667 $125 Million
Q1 2024 May 15, 2024	SELL	$146.51 - $198.2 $4.59 Million - $6.21 Million	-31,349 Reduced 10.76%	260,019 $38.9 Million
Q4 2023 Feb 13, 2024	SELL	$151.41 - $196.57 $3.13 Million - $4.06 Million	-20,677 Reduced 6.63%	291,368 $55.8 Million
Q3 2023 May 14, 2024	BUY	$170.77 - $211.65 $3.53 Million - $4.38 Million	20,677 Added 7.1%	312,045 $55.3 Million
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $9.59 Million - $11.9 Million	56,152 Added 21.94%	312,045 $55.3 Million
Q2 2023 May 14, 2024	BUY	$185.01 - $212.05 $4.76 Million - $5.45 Million	25,707 Added 11.17%	255,893 $48.6 Million
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $4.76 Million - $5.45 Million	25,707 Added 11.17%	255,893 $48.6 Million
Q1 2023 May 14, 2024	SELL	$182.66 - $235.53 $29.7 Million - $38.3 Million	-162,575 Reduced 41.39%	230,186 $46.1 Million
Q1 2023 May 11, 2023	SELL	$182.66 - $235.53 $29.7 Million - $38.3 Million	-162,575 Reduced 41.39%	230,186 $46.1 Million
Q4 2022 May 14, 2024	SELL	$185.53 - $241.31 $13.5 Million - $17.5 Million	-72,546 Reduced 15.59%	392,761 $93.3 Million
Q4 2022 Feb 13, 2023	SELL	$185.53 - $241.31 $13.5 Million - $17.5 Million	-72,546 Reduced 15.59%	392,761 $93.3 Million
Q3 2022 May 14, 2024	SELL	$138.54 - $232.0 $1.67 Million - $2.8 Million	-12,067 Reduced 2.53%	465,307 $93.1 Million
Q3 2022 Nov 10, 2022	SELL	$138.54 - $232.0 $1.67 Million - $2.8 Million	-12,067 Reduced 2.53%	465,307 $93.1 Million
Q2 2022 May 14, 2024	BUY	$120.42 - $169.29 $22.4 Million - $31.5 Million	186,006 Added 63.84%	477,374 $69.6 Million
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $24.6 Million - $34.6 Million	-204,179 Reduced 29.96%	477,374 $69.6 Million
Q1 2022 May 16, 2022	SELL	$127.18 - $173.91 $653,959 - $894,245	-5,142 Reduced 0.75%	681,553 $111 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $3.23 Million - $4.24 Million	20,240 Added 3.04%	686,695 $116 Million
Q3 2021 Nov 10, 2021	BUY	$169.75 - $207.73 $113 Million - $138 Million	666,455 New	666,455 $126 Million

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Alnylam Pharmaceuticals, Inc. Transaction History